Brokers Issue Forecasts for Heron Therapeutics, Inc.’s Q3 2017 Earnings (HRTX)
Heron Therapeutics, Inc. (NASDAQ:HRTX) – Jefferies Group raised their Q3 2017 EPS estimates for shares of Heron Therapeutics in a research report issued on Wednesday. Jefferies Group analyst B. Amin now forecasts that the biotechnology company will post earnings of ($0.89) per share for the quarter, up from their previous estimate of ($0.99). Jefferies Group currently has a “Buy” rating and a $26.00 target price on the stock. Jefferies Group also issued estimates for Heron Therapeutics’ Q4 2017 earnings at ($0.96) EPS, FY2017 earnings at ($3.52) EPS, FY2018 earnings at ($2.28) EPS and FY2019 earnings at ($1.00) EPS.
HRTX has been the topic of a number of other research reports. Zacks Investment Research downgraded Heron Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 9th. Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Friday, May 12th. Cowen and Company set a $40.00 target price on Heron Therapeutics and gave the company a “buy” rating in a report on Thursday, August 3rd. Aegis reaffirmed a “buy” rating and issued a $33.00 target price on shares of Heron Therapeutics in a report on Tuesday, July 18th. Finally, ValuEngine raised Heron Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. One analyst has rated the stock with a sell rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $31.00.
COPYRIGHT VIOLATION NOTICE: “Brokers Issue Forecasts for Heron Therapeutics, Inc.’s Q3 2017 Earnings (HRTX)” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/14/brokers-issue-forecasts-for-heron-therapeutics-inc-s-q3-2017-earnings-hrtx.html.
Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 16.00 on Monday. The stock’s 50 day moving average price is $15.38 and its 200-day moving average price is $14.57. Heron Therapeutics has a 52-week low of $12.21 and a 52-week high of $22.01.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million during the quarter, compared to the consensus estimate of $4.53 million.
Several large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc increased its stake in Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 1,098 shares during the period. Venturi Wealth Management LLC purchased a new stake in Heron Therapeutics during the first quarter valued at $161,000. Quantbot Technologies LP increased its stake in Heron Therapeutics by 2,619.6% in the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 12,024 shares during the period. Highbridge Capital Management LLC increased its stake in Heron Therapeutics by 1.6% in the fourth quarter. Highbridge Capital Management LLC now owns 15,697 shares of the biotechnology company’s stock valued at $206,000 after buying an additional 252 shares during the period. Finally, Old West Investment Management LLC purchased a new stake in Heron Therapeutics during the first quarter valued at $206,000.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.